307 related articles for article (PubMed ID: 27167192)
1. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
[TBL] [Abstract][Full Text] [Related]
2. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
3. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis.
Chen SL; Liu LL; Lu SX; Luo RZ; Wang CH; Wang H; Cai SH; Yang X; Xie D; Zhang CZ; Yun JP
Mol Oncol; 2017 Sep; 11(9):1225-1240. PubMed ID: 28580773
[TBL] [Abstract][Full Text] [Related]
4. USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma.
Lu C; Ning Z; Wang A; Chen D; Liu X; Xia T; Tekcham DS; Wang W; Li T; Liu X; Liu J; Qi H; Luo H; Du J; Ma C; Yan Q; Liu J; Xu G; Piao HL; Tan G
Cancer Lett; 2018 Nov; 436():139-148. PubMed ID: 30056112
[TBL] [Abstract][Full Text] [Related]
5. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
[TBL] [Abstract][Full Text] [Related]
7. Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling.
Li M; Jin C; Xu M; Zhou L; Li D; Yin Y
Cell Commun Signal; 2017 Dec; 15(1):52. PubMed ID: 29246230
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway.
Zhang Y; Guo X; Xiong L; Yu L; Li Z; Guo Q; Li Z; Li B; Lin N
Mol Cancer; 2014 Nov; 13():253. PubMed ID: 25424347
[TBL] [Abstract][Full Text] [Related]
9. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
10. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.
Ji J; Tang J; Deng L; Xie Y; Jiang R; Li G; Sun B
Oncotarget; 2015 Dec; 6(40):42813-24. PubMed ID: 26540343
[TBL] [Abstract][Full Text] [Related]
11. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
12. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
[TBL] [Abstract][Full Text] [Related]
13. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
15. Pivotal role of mTOR signaling in hepatocellular carcinoma.
Villanueva A; Chiang DY; Newell P; Peix J; Thung S; Alsinet C; Tovar V; Roayaie S; Minguez B; Sole M; Battiston C; Van Laarhoven S; Fiel MI; Di Feo A; Hoshida Y; Yea S; Toffanin S; Ramos A; Martignetti JA; Mazzaferro V; Bruix J; Waxman S; Schwartz M; Meyerson M; Friedman SL; Llovet JM
Gastroenterology; 2008 Dec; 135(6):1972-83, 1983.e1-11. PubMed ID: 18929564
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
17. mTOR up-regulation of SNRPA1 contributes to hepatocellular carcinoma development.
Feng J; Guo J; Zhao P; Shen J; Chai B; Wang J
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32420585
[TBL] [Abstract][Full Text] [Related]
18. AIM2 inhibits colorectal cancer cell proliferation and migration through suppression of Gli1.
Xu M; Wang J; Li H; Zhang Z; Cheng Z
Aging (Albany NY); 2020 Dec; 13(1):1017-1031. PubMed ID: 33291082
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development.
Cheng H; Xue J; Yang S; Chen Y; Wang Y; Zhu Y; Wang X; Kuang D; Ruan Q; Duan Y; Wang G
Oncotarget; 2017 Jul; 8(29):47984-47997. PubMed ID: 28624790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
